DMAC earnings: real EPS beat/miss history, analyst consensus Buy, P/E -9.77. Updated 2026-07-23.
DiaMedica Therapeutics (DMAC) Research Hub
DiaMedica Therapeutics (DMAC) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 6.47 USD (-1.82%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -9.77, market cap 0.38B. This hub links to the full technical, earnings and options research available for DMAC.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 6.47 USD (-1.82%) |
| 52-week range | 5.56 USD – 8.53 USD |
| Trend regime | Range |
| 14-day RSI | 43.5 (Bearish) |
| Trailing P/E | -9.77 |
| Market cap | 0.38B |
| Dividend yield | 0.00% |
Available research for DMAC
Covered Call on DMAC: how it works, illustrative setup around the real 6.47 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on DMAC: how it works, illustrative setup around the real 6.47 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on DMAC: how it works, illustrative setup around the real 6.47 USD price, max profit/loss, breakeven and when to use it. Educational.
DMAC technical analysis: range, last 6.47 USD, RSI 43.5, 52w range 5.56 USD–8.53 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is DMAC in?
DiaMedica Therapeutics (DMAC) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is DMAC in an uptrend or downtrend?
As of 2026-09-11, DMAC is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is DMAC's trailing P/E ratio?
DMAC's trailing P/E is -9.77, with a market cap of 0.38B. See the earnings research page for full valuation detail.